ViroStatics

What ViroStatics does

ViroStatics is a small, privately held pharmaceutical company headquartered in Sassari, Italy, that develops novel compounds intended for the multifaceted treatment of cancers and viral diseases. Founded in 2005 and operating with 11-50 employees, the company is built around proprietary small-molecule research rather than a marketed product portfolio; the publicly stated functional scope is therapeutic discovery across oncology and antiviral indications.

Capital formation has been limited and dated: the two recorded funding events are a $52,680 instrument from EISMEA in March 2017 and a nominal-value event involving GM&C Life Sciences Fund in September 2016. No subsequent funding rounds, partnerships, licensing deals, M&A activity, or product launches are documented in the available data, and the company website currently resolves to a bot-verification page that yields no operational content. Leadership disclosure is limited to Franco Lori, who serves as both CEO and Chairman of the Board, indicating concentrated founder-led governance.

Because no revenue, pricing, customer, distribution, or pipeline progression data is available, the commercial mechanics of the business cannot be characterized beyond the inference that ViroStatics operates as a research-stage biotech. The combination of very small prior capital raises, a 20+ year gap since last recorded funding, and a single named executive materially constrains the conclusions that can be drawn about the company's current operating scale, momentum, or strategic trajectory.

Name

ViroStatics

Website

https://virostatics.com

Company type

Private

Founded year

2005

Headcount range

11–50 employees

Short description

ViroStatics is a small, privately held Italian pharmaceutical company that develops novel compounds for the multifaceted treatment of cancers and viral diseases, operating as a research-stage biotech from Sassari since 2005.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Oncology drug development
• Antiviral drug discovery
• Novel compound synthesis
• Pharmaceutical research
• Cancer therapeutics

Headquarters

HQ city

Sassari

HQ country

Italy

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

ViroStatics is a pharmaceutical research company that discovers and develops novel chemical compounds intended for the multifaceted treatment of cancer and viral diseases. Its work is centered on proprietary small-molecule compounds applied through a multi-target therapeutic framework, with the company positioning itself as an early-stage drug-discovery laboratory rather than a commercial-stage therapeutics business.

Differentiator

Problem solved

Functional benefit

Products and services

• Novel compound R&D for cancers and viral diseases An early-stage pharmaceutical R&D effort that develops proprietary novel chemical compounds intended for the multifaceted, multi-target treatment of cancers and viral diseases, addressing the unmet needs of larger pharmaceutical partners and ultimately patients with oncology or viral indications.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Direct peers

• Philogen: Italian-Swiss biotech developing targeted therapeutics primarily in oncology. Comparable to ViroStatics as a small, European, privately-oriented drug discovery company operating from Italy with focused oncology R&D.
• Newron Pharmaceuticals: Italian biopharmaceutical company developing novel therapies for central nervous system and rare diseases. Comparable as another small Italian-headquartered drug discovery company with a focused, single-platform therapeutic approach.
• BioCryst Pharmaceuticals: US biotech focused on small-molecule antiviral and rare disease therapeutics. Comparable to ViroStatics' antiviral therapeutic orientation and small-molecule discovery modality, though more clinically advanced.
• Chimerix: Small-cap US biotech developing antiviral therapeutics. Comparable through its small-molecule antiviral focus and similar scale-to-pipeline ratio.
• Nerviano Medical Sciences: Italian oncology drug discovery company focused on small-molecule kinase inhibitors. Comparable as an Italy-based, oncology-focused small-molecule discovery organization with similar early-stage profile.
• Atea Pharmaceuticals: Clinical-stage biotech developing antiviral therapeutics including direct-acting antivirals. Comparable to ViroStatics' antiviral discovery orientation and small-molecule approach.

Broad incumbents

• PharmaMar: Spanish biopharmaceutical company developing marine-derived anticancer compounds. Comparable as a European oncology-focused small-molecule developer with commercial-stage assets, though materially larger and more advanced than ViroStatics.
• Hoffmann-La Roche: Global pharmaceutical leader with major oncology and antiviral franchises. Comparable as the dominant incumbent ViroStatics competes against in both its stated therapeutic areas.
• Servier: European pharmaceutical company with significant oncology R&D investment. Comparable as a broader European pharma incumbent whose oncology focus overlaps ViroStatics' stated therapeutic area.

Regional players

• Genenta Science: Italian clinical-stage biotech developing gene therapies for cancer. Comparable as another small Italian-headquartered oncology biotech, though focused on cell/gene therapy rather than small molecules.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViroStatics